|
Tasly Pharmaceutical Group Co., Ltd (600535.SS) Avaliação DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Tasly Pharmaceutical Group Co., Ltd (600535.SS) Bundle
Descubra o verdadeiro potencial da Tasly Pharmaceutical Group Co., Ltd (600535Ss) com nossa calculadora DCF avançada! Ajuste as suposições essenciais, explore vários cenários e avalie como as flutuações influenciam a avaliação da Tasly Pharmaceutical Group Co., Ltd (600535Ss) - tudo dentro de um modelo conveniente do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13,576.1 | 7,952.0 | 8,593.2 | 8,674.0 | 8,498.1 | 7,766.2 | 7,097.4 | 6,486.1 | 5,927.5 | 5,417.0 |
| Revenue Growth, % | 0 | -41.43 | 8.06 | 0.94045 | -2.03 | -8.61 | -8.61 | -8.61 | -8.61 | -8.61 |
| EBITDA | 2,342.9 | 3,424.5 | 448.3 | 1,808.5 | 1,626.2 | 1,639.1 | 1,497.9 | 1,368.9 | 1,251.0 | 1,143.2 |
| EBITDA, % | 17.26 | 43.06 | 5.22 | 20.85 | 19.14 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 |
| Depreciation | 590.0 | 503.0 | 532.7 | 504.9 | 496.2 | 443.1 | 405.0 | 370.1 | 338.2 | 309.1 |
| Depreciation, % | 4.35 | 6.33 | 6.2 | 5.82 | 5.84 | 5.71 | 5.71 | 5.71 | 5.71 | 5.71 |
| EBIT | 1,752.9 | 2,921.5 | -84.4 | 1,303.6 | 1,130.0 | 1,195.9 | 1,092.9 | 998.8 | 912.8 | 834.1 |
| EBIT, % | 12.91 | 36.74 | -0.98256 | 15.03 | 13.3 | 15.4 | 15.4 | 15.4 | 15.4 | 15.4 |
| Total Cash | 2,118.8 | 3,791.4 | 4,234.8 | 4,751.3 | 3,518.3 | 3,242.3 | 2,963.1 | 2,707.9 | 2,474.6 | 2,261.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5,197.6 | 3,795.6 | 3,347.7 | 2,163.1 | .0 | 2,328.5 | 2,128.0 | 1,944.7 | 1,777.2 | 1,624.1 |
| Account Receivables, % | 38.28 | 47.73 | 38.96 | 24.94 | 0.0000000118 | 29.98 | 29.98 | 29.98 | 29.98 | 29.98 |
| Inventories | 1,353.7 | 1,547.9 | 1,515.9 | 1,747.7 | 1,711.9 | 1,357.1 | 1,240.2 | 1,133.4 | 1,035.8 | 946.6 |
| Inventories, % | 9.97 | 19.47 | 17.64 | 20.15 | 20.14 | 17.47 | 17.47 | 17.47 | 17.47 | 17.47 |
| Accounts Payable | 296.7 | 265.7 | 373.4 | 497.1 | 606.8 | 353.3 | 322.8 | 295.0 | 269.6 | 246.4 |
| Accounts Payable, % | 2.19 | 3.34 | 4.35 | 5.73 | 7.14 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 |
| Capital Expenditure | -408.8 | -571.7 | -403.4 | -668.8 | -564.9 | -454.4 | -415.3 | -379.5 | -346.8 | -316.9 |
| Capital Expenditure, % | -3.01 | -7.19 | -4.69 | -7.71 | -6.65 | -5.85 | -5.85 | -5.85 | -5.85 | -5.85 |
| Tax Rate, % | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 |
| EBITAT | 1,354.5 | 2,530.3 | -179.3 | 1,143.5 | 1,010.4 | 1,054.8 | 964.0 | 880.9 | 805.1 | 735.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4,718.9 | 3,638.4 | 537.5 | 2,056.1 | 3,250.2 | -1,183.6 | 1,240.7 | 1,133.8 | 1,036.2 | 946.9 |
| WACC, % | 6.17 | 6.2 | 6.23 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 | 6.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,447.6 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 980 | |||||||||
| Terminal Value | 36,283 | |||||||||
| Present Terminal Value | 26,857 | |||||||||
| Enterprise Value | 29,304 | |||||||||
| Net Debt | -1,972 | |||||||||
| Equity Value | 31,277 | |||||||||
| Diluted Shares Outstanding, MM | 1,493 | |||||||||
| Equity Value Per Share | 20.95 |
What You Will Gain
- Authentic (600535SS) Financial Data: Pre-loaded with Tasly Pharmaceutical's historical and projected figures for accurate analysis.
- Completely Customizable Template: Easily adjust key parameters such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch the intrinsic value of Tasly Pharmaceutical update in real-time as you make adjustments.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for reliable DCF outputs.
- User-Friendly Interface: Designed with a straightforward layout and clear guidance suitable for all skill levels.
Key Features
- Comprehensive DCF Tool: Features detailed unlevered and levered DCF valuation frameworks.
- WACC Calculator: A ready-to-use Weighted Average Cost of Capital worksheet with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investment assumptions, and discount rates.
- Integrated Financial Metrics: Assess profitability, leverage, and efficiency metrics for Tasly Pharmaceutical Group Co., Ltd (600535SS).
- Interactive Dashboard and Visuals: Graphical representations provide a clear overview of essential valuation indicators for quick analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Tasly Pharmaceutical Group Co., Ltd's (600535SS) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including the intrinsic value of Tasly Pharmaceutical Group Co., Ltd (600535SS).
- Step 5: Use the outputs to make informed investment choices or create comprehensive reports.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and industry consultants.
- Accurate Data: Tasly Pharmaceutical's historical and projected financials are preloaded for precise calculations.
- Flexibility in Analysis: Effortlessly simulate various forecasts and assumptions.
- Clear Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step instructions lead you through the entire process.
Who Should Use This Product?
- Professional Investors: Create comprehensive and precise valuation models for portfolio assessments related to Tasly Pharmaceutical Group Co., Ltd (600535SS).
- Corporate Finance Teams: Examine valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver accurate valuation insights for clients interested in Tasly Pharmaceutical Group Co., Ltd (600535SS).
- Students and Educators: Utilize real-world data for practicing and teaching financial modeling techniques.
- Pharmaceutical Industry Enthusiasts: Gain insights into how companies like Tasly Pharmaceutical Group Co., Ltd (600535SS) are valued in the marketplace.
What the Template Contains
- Historical Data: Includes Tasly Pharmaceutical’s past financial performance and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to assess Tasly Pharmaceutical's intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Adjust key drivers such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A comprehensive breakdown of Tasly Pharmaceutical’s financials.
- Interactive Dashboard: Dynamically visualize valuation results and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.